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  Introduction: The importance of resolving the problem of premenstrual syndrome for 
patients has been emphasized due to its direct and indirect economical effects on the 
society. The aim of the current study was to evaluate the effects of magnesium and 
vitamin  B6  on  the  severity  of  premenstrual  syndrome  in  patients  referring  to  health 
centers  affiliated  to  Isfahan  University  of  Medical  Sciences,  Iran,  during  2009-10. 
Methods: This two-stage double-blind clinical trial was conducted on 126 women who 
were randomly allocated into 3 groups to receive magnesium, vitamin B6, or placebo. 
The  study  was  performed  in  10  selected  health  centers  in  Isfahan  and  lasted  for  4 
months. To confirm premenstrual syndrome, the participants were asked to complete a 
menstrual diary for 2 months at home. Drug interventions were continued for two cycles 
and the results of before and after the intervention were compared. Results: The findings 
of  this  study  showed  that  the  mean  scores  of  premenstrual  syndrome  significantly 
decreased after the intervention in all groups (p < 0.05). Conclusion: According to our 
findings, vitamin B6 and placebo had the most and least efficiency in improving the 
mean premenstrual syndrome score. 
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Introduction  
Premenstrual  syndrome  affects  millions  of 
women and is known as the most important 
disorder  in  women.1  It  has  been  estimated 
that  80-90%  of  women  of  reproductive  age 
experience  the  symptoms  of  this  syndrome 
and  3-8%  of  these  women  have  severe 
symptoms.2 In Iran, Bakhshani et al. studied 
the  students  of  Zahedan  University  of 
Medical  Sciences  and  calculated  the 
prevalence  of  this  syndrome  to  be  16%.3 
Moreover, Tamjidi reported the prevalence of 
premenstrual  syndrome  among  15-49  year-
old  women  of  Tehran,  Iran  as  62.4%.4 
Likewise, Soltan Ahmadi suggested the rate 
as  66.5%  in  female  senior  students  of  high 
school in Kerman, Iran.5 A study by Sheikh 
Al  Eslami  on  100  patients  with  major 
depression in two centers in Tehran revealed 
the prevalence of this syndrome to be 76%.6  
According to the diagnostic criteria of the 
American  Psychiatric  Association  (APA), 
premenstrual  syndrome  is  confirmed  by 
keeping  a  menstrual  diary.  Recording  a 
minimum  of  5  symptoms  which  persist 
during the last week of luteal phase until the 
first  4  days  of  the  next  cycle  for  at  least  2 
consecutive  cycles  and  that  interfere  with 
work or daily activities and communication 
but  are  not  due  to  mental  disorders  would 
suggest premenstrual syndrome.7 
Hitherto,  numerous  etiologies  have  been 
proposed  to  explain  this  disorder,  and 
consequently various treatment methods have 
been  suggested  for  controlling  its  clinical 
symptoms.  This  is  largely  due  to  the 
multifactorial nature of the disorder and the 
role of different biological, psychological, and 
social factors in its occurrence. In addition, the Ebrahimi et al. 
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overlapping  of  its  symptoms  with  many 
psychiatric  disorders  and  women's  diseases 
might  also  be  responsible.8  One  of  the 
proposed  treatments  for  this  syndrome  is 
magnesium. Abraham was the first person to 
propose magnesium deficiency as one of the 
factors causing and intensifying premenstrual 
syndrome symptoms. He justified this relation 
through  the  calming  effect  of  magnesium  in 
controlling  neuromuscular  stimulation.9  The 
magnesium  content  of  erythrocytes  and 
leukocytes  of  women  with  premenstrual 
syndrome  has  been  found  to  be  lower  than 
other women.10 
Vitamin B6 is another proposed treatment 
for this syndrome. On the one hand vitamin 
B6  increases  serotonin  and  dopamine  levels 
and  improves  premenstrual  syndrome 
symptoms, and on the other, it has an essential 
role in the synthesis of prostaglandin and fatty 
acids, which are reduced in etiologies causing 
premenstrual  syndrome.11  Moreover, 
researchers believe that vitamin B6 deficiency 
decreases  dopamine  in  the  kidneys  and 
therefore increase sodium excretion, which in 
turn  causes  water  accumulation  in  the  body 
and  induces  symptoms  such  as  swelling  in 
extremities, edema, and abdominal and chest 
discomfort. The administration of vitamin B6 
can  thus  decrease  these  symptoms  and 
improve  premenstrual  acne.12  Numerous 
studies  on  the  effectiveness  of  these 
compounds on premenstrual syndrome have 
reported  indefinite  findings.  Therefore, 
proving  the  effectiveness  of  these  drugs  on 
treatment of premenstrual syndrome requires 
further research. Considering the importance of 
this syndrome in individual and social issues, 
and the fact that magnesium and vitamin B6 
are low-priced, accessible, and safe, this study 
aimed  to  determine  the  effects  of  these 
compounds on premenstrual syndrome. 
Materials and methods 
This  study  was  a  double-blind  clinical  trial 
with  placebo.  To  ensure  the  double-blind 
design,  the  drug  boxes  were  coded  by  the 
researcher's coworker. The  boxes were  then 
 distributed  by  the  researcher.  The 
participants  and  researchers  were  thus 
unaware  of  the  coding until  the  end  of  the 
study  and  after  decoding.  The  study  was 
confirmed  by  ethics  committee  of  Isfahan 
University of Medical Sciences, Isfahan, Iran.  
After  evaluating  the  inclusion  and 
exclusion  criteria,  a  questionnaire  was 
completed  to  assess  the  symptoms  for 
temporary  diagnosis  of  premenstrual 
syndrome.  Depression  and  stress  were  also 
studied using the Beck depression inventory 
and  the  Holmes  and  Rahe  stress  scale, 
respectively. The participants without proved 
depression  and  anxiety  were  provided  with 
menstrual  diary  forms.  They  were  asked  to 
complete  the  forms  for  2  months.  The 
menstrual  diary  form  is  a  standardized  tool 
for confirming the existence and determining 
the  severity  of  premenstrual  syndrome 
symptoms.  It  can  be  easily  used  by  patients 
and interpreted by physicians.13 This form has 
been used in different books and articles with 
a  correlation  coefficient  of  92%.14  Moreover, 
Pakgohar et al. collaborated with teachers and 
faculty  members  of  Tehran  University  of 
Medical Sciences and confirmed the validity of 
the  questionnaire  used  in  this  study  using 
content validity in 2004. They also reported a 
Pearson's correlation coefficient of r = 0.92 for 
the reliability of this questionnaire.15  
The participants in the current study were 
15-45 year-old women who referred to selected 
health centers and suffered from premenstrual 
syndrome  according  to  the  American 
Psychiatric  Association  criteria.  Women  were 
included if they had a regular menstrual cycle, 
did  not  suffer  from  depression,  anxiety,  or 
acute  or  chronic  illnesses,  did  not  use  any 
drugs  or  supplements,  and  did  not  exercise 
regularly. The exclusion criteria of the current 
study  were  pregnancy,  using  hormonal 
methods  of  contraception  or  any  other 
hormonal  drugs,  lack  of  commitment  to 
correct  usage  of  medications  and  regular 
completion of the forms, and unwillingness to 
continue the treatment. 
In order to perform sampling, 10 centers Premenstrual syndrome and vitamins and minerals  
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were randomly selected (drawing method) 
from  the health  centers  affiliated  to Isfahan 
University of Medical Sciences. The number 
of subjects from each center was determined 
according  to  the  population  covered  by  the 
center using quota method. The participants 
were  then  randomly  selected  from  patients 
who  referred  to  the  centers  and  had  the 
inclusion criteria.  
This study was conducted in two stages. 
In the first stage, 150 patients were entered 
into  the  study  to  complete  the  menstrual  
diary.  Although  138  subjects  returned  their 
forms,  analyzing  the  forms  revealed  126 
women  to  have  premenstrual  syndrome. 
These participants were randomly (according 
to  their  order  of  referring)  placed  into  3 
groups  of  42.  Patients  in  the  magnesium, 
vitamin B6, and control groups received one 
250 mg magnesium tablet, vitamin B6 tablets, 
and placebo, respectively. All tablets looked 
similar and were provided by the Faculty of 
Pharmacy,  Isfahan  University  of  Medical 
Sciences,  Isfahan,  Iran.  In  the  second  stage, 
the participants were asked to complete the 
menstrual diary and use the drugs from the 
first  day  of  their  menstrual  cycle  to  the 
beginning  of  the  next  cycle.  Finally,  36 
patients from the vitamin B6 group, 38 from 
the  magnesium  group,  and  37  from  the 
control group cooperated with the researcher 
until the end of the study.  
The severity of symptoms was determined 
based  on  the  menstrual  diary  and  rating  of 
symptoms.  Participants  rated  the  severity  of 
symptoms as 0-3 in their forms. While absence 
of the symptom was scored as 0, scores of 1 to 
3  indicated  mild  symptoms  which  did  not 
interfere  with  daily  activities  such  as 
education  and  work,  moderate  symptoms 
which affected daily activities to some extent, 
and  severe  symptoms  which  prevented  the 
 patient from daily activities, respectively. 
Results 
In  the  current  study,  the  mean  age  of 
participants  in  the  two  intervention  groups 
and  the  control  group  was  28.71  and  28.03 
years,  respectively.  The  three  groups  were 
similar in terms of marital status, education 
level,  method  of  contraception,  job,  weight, 
height, number of children, age of menarche, 
the time between bleedings, and duration of 
bleeding (p > 0.05). 
Moreover, no significant differences in the 
mean  scores  of  premenstrual  syndrome 
symptoms  were  found  between  the  two 
intervention  groups  and  the  control  group 
before  treatment  (p  =  0.76).  However,  a 
significant  difference  was  observed  between 
the 3 groups after treatment (p < 0.05). Table 1 
presents  the  mean  scores  of  premenstrual 
syndrome  before  and  after  intervention  in 
each group. As it is seen, the mean scores of 
premenstrual  syndrome  symptoms  were 
similar in the 3 groups (range: 35-37) before 
the intervention. One-way analysis of variance 
(ANOVA)  showed  no  significant  difference 
between the groups in this respect (p > 0.05). 
The  table  shows  that  the  subjects  were 
randomly allocated into the 3 groups since the 
mean scores of premenstrual syndrome in all 
groups  are  in  the  same  range  before  the 
intervention.  Paired  t-test  showed  that  the 
mean scores of premenstrual syndrome in all 
groups  decreased  significantly  after  the 
intervention  in  comparison  to  before  the 
intervention  (p  <  0.05).  On  the  other  hand, 
Tukey's  test  revealed  a  significant  statistical 
difference between B6 and magnesium groups 
and magnesium and placebo groups (p < 0.05 
for both). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Scores of premenstrual syndrome before and after the intervention in the 
three groups 
  Magnesium  Vitamin B6  Placebo 
Before the intervention  36.89 (7.27)  36.51 (7.06)  35.8 (6.76) 
After the intervention  22.22 (4.69)  22.84 (6.76)  28.41 (4.33) 
p  < 0.001  < 0.001  < 0.001 
Values are expressed as mean (SD) 
 Ebrahimi et al. 
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To  simplify  the  comparisons  between 
groups in terms of effectiveness on reducing 
each  symptom,  30  symptoms  of  the 
menstrual  diary  were  divided  into  5 
subgroups  according  to  the  Abraham's 
classification.9  The  effectiveness  of  each 
compound  on  the  symptoms  was  then 
evaluated  in  detail.  The  subgroups  were  as 
follows: 
 Craving: Craving for sweets, palpitation, 
feeling  weak,  decreased  energy,  increased 
appetite, and fatigue;   
 Depression:  Depression  and  seclusion, 
social inactivity, crying, impatience, the desire 
to  stay  at  home,  anger,  forgetfulness, 
insomnia, and lack of concentration; 
 Anxiety: Stress, irritability, and anxiety;     
  Water  retention:  Pain  and  breast 
tenderness,  swelling  of  the  legs,  and 
abdominal bloating, pain, and discomfort; 
 Somatic  changes:  Feeling  cold,  nausea, 
frequent  urination,  hot  flashes,  back  pain, 
headaches,  acne,  oily  skin,  joint  pain,  and 
muscle pain. 
The  effects  of  each  intervention  on  the 
subgroups  of  syndrome  symptoms  are 
summarized  in  Table  2.  According  to 
ANOVA, scores of craving did not decrease 
significantly after the intervention (p = 0.2). 
However, the differences were significant in 
other  subgroups  of  syndrome  symptoms  
(p  <  0.001  in  all  cases).  Vitamin  B6  and 
magnesium  were  most  effective  in  the 
subgroups  of  depression,  water  retention, 
and anxiety. The two interventions were also 
similar in improving somatic symptoms.  
Discussion 
In  accordance  with  previous  research,  the 
findings  of  this  study  demonstrated  the 
positive effects of magnesium and vitamin B6 
on  reduction  of  all  premenstrual  syndrome 
symptoms.  Facchinetti  et  al.  found  that 
compared  to  placebo,  a  two-month 
intervention  with  magnesium  significantly 
reduced the mean total score of premenstrual 
syndrome (p < 0.04). Magnesium particularly 
caused significant reductions in the severity 
of symptoms of water retention (p < 0.03) and 
pain (p < 0.04).16 The higher effectiveness of 
magnesium  on  a  greater  number  of 
symptoms of the syndrome in our study in 
comparison to the study by Facchinetti et al. 
may  be  due  to  the  pattern  of  magnesium 
usage in the current study. We prescribed a 
250 mg magnesium oxide tablet from the first 
day of menstrual cycle until the beginning of 
the next cycle while Facchinetti et al. used a 
360  mg  magnesium  tablet  in  the  form  of 
pyrrolidone  carboxylic  acid  from  day  15  of 
the cycle to the beginning of the next cycle.16 
On  the  other  hand,  the  available  literature 
suggests the daily requirement of magnesium 
in  an  adult  to  be  320  mg.  In  addition,  the 
kidneys  of  a  healthy  person  excrete  excess 
magnesium  into  the  urine  to  avoid 
magnesium  poisoning.17  Therefore, 
prescribing  a  higher  dosage  in  a  shorter 
period of time does not reduce the symptoms 
since  the  excess  magnesium  is  excreted.  In 
the study by Quaranta et al. on the efficacy 
and safety of a slow-release magnesium 250 
mg  tablet  (Sincromag)  for  the  treatment  of 
premenstrual  syndrome  on  41  patients, 
magnesium  showed  the  highest  efficacy  on 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Comparison of changes in mean premenstrual syndrome scores before and after the 
intervention in each group  
  Magnesium  Vitamin B6  Placebo  f  p 
Craving  -23.04 (19.49)  -19.37 (16.62)  -14.09 (18.97)  1.56  0.20 
Depression  -17.3 (18.26)  -23.43 (17.26)  -13.33 (18.38)  6.4  < 0.001 
Water retention  -15.39 (16.39)  -11.28 (15.74)  -5.2 (17.30)  6.81  < 0.001 
Anxiety  -12.14 (26.14)  -11.19 (19)  0.000 (20.41)  6.34  < 0.001 
Somatic changes  -12.73 (16.87)  -12.8 (19.52)  -2.5 (16.97)  4.55  0.005 
Values are expressed as mean (SD) 
The  mean  changes  are  negative  due  to  the  reduction  of  syndrome  symptoms  after  the  intervention  in  comparison  to  before  the 
intervention 
 Premenstrual syndrome and vitamins and minerals  
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reducing  depression,  craving,  and  anxiety. 
The  effectiveness  of  magnesium  was  also 
higher  than  placebo  in  improving  other 
symptoms.14  Walker  et  al.  reported 
magnesium to cause a significant decrease in 
the  severity  of  symptoms  related  to  water 
retention  after  2  months  of  prescription  
(p = 0.009).18 Although, magnesium improved 
all  symptoms  of  premenstrual  syndrome  in 
this  study,  this  improvement  was  not 
significant.  The  difference  between  the 
findings of Walker et al. and the current study 
might  have  been  due  to  the  younger  age  of 
their  participants  (15-25  vs.  28-30  years).  In 
fact, younger age could have been associated 
with consuming more chocolate, sweets, and 
caffeine  and  thus  more  severe  symptoms 
which reduced the effects of the drugs. 
Sharma  et  al.  evaluated  the  efficiency  of 
vitamin  B6  on  60  patients  suffering  from 
premenstrual syndrome in India. They found 
the mean score of premenstrual syndrome to 
decrease from 30.15 to 14.7 (16 points) in the 
second  month  of  using  100  mg  vitamin  B6 
daily.17 We however, could not establish such 
a reduction which might have been caused by 
the  higher  severity  of  the  syndrome  in  our 
participants  (36.51,  i.e.  in  the  moderate 
intensity  range  of  premenstrual  syndrome) 
compared  to  the  subjects  in  the  study  by 
Sharma et al. (30.15, i.e. in the mild intensity 
range  of premenstrual syndrome).  Reviewing 
scientific literature on vitamin B6 shows that its 
effectiveness does not depend on its dosage. 
Table 2 would be helpful in comparing the 
efficacy of vitamin B6 and other compounds 
on each symptom of premenstrual syndrome. 
The  table  shows  that  vitamin  B6  most 
efficiently  reduced  depression-related 
symptoms  of  premenstrual  syndrome. 
Maroofi  et  al.  assessed  the  effectiveness  of 
vitamin B6 on premenstrual syndrome in 94 
patients in Isfahan. They found that using 40 
mg  vitamin  B6,  in  comparison  to  placebo, 
will cause a significant reduction in the mood 
symptoms  of  premenstrual  syndrome  
(p = 0.001). They thus suggested vitamin B6 
as  an  effective  drug  in  reducing  mood 
symptoms of premenstrual syndrome.19 In a 
study  on  93  patients  with  premenstrual 
syndrome,  Dolatian  et  al.  reported  that 
compared to placebo and vitamin E, the daily 
usage  of  40  mg  of  vitamin  B6  would 
significantly  improve  somatic  changes  of 
premenstrual  syndrome,  such  as  pain, 
abdominal  discomfort,  back  pain,  oily  skin, 
muscle pain, and breast pain and tenderness 
after 2 months (p < 0.03).20 These symptoms 
fall  in  the  subgroup  of  water  retention  of 
physical symptoms in the current study. On 
the  contrary,  vitamin  B6  was  less  effective 
than vitamin E in reducing mood symptoms 
of  premenstrual  syndrome.20  In  a  study  by 
Salehi  and  Salehi  on  92  patients,  a  daily 
dosage of 200 mg of vitamin B6 significantly 
decreased  depression,  anxiety,  drowsiness, 
and  breast  tenderness  in  comparison  to 
placebo (p < 0.05).21  
As  Table 2  shows,  vitamin  B6 was more 
effective  than  magnesium  on  symptoms 
related to depression. However, symptoms of 
craving,  water  retention,  and  anxiety  were 
better controlled by magnesium. Desouza et 
al. suggested vitamin B6 to be more efficient 
than  magnesium  in  relieving  symptoms 
related to depression (107% vs. 88%) which is 
in  accordance  with  the  current  study. 
However,  in  contrast  to  the  present  study, 
they found vitamin B6 to be more effective 
than magnesium in relieving other symptoms 
as well.22 This difference may have resulted 
from the longer duration of the intervention 
in the current study since magnesium oxide 
needs  at  least  2  months  to  show  its 
therapeutic  properties  on  premenstrual 
syndrome.  The  reason  might  be  the  low 
bioavailability  of  magnesium  oxide  which 
necessitates a longer time for the compound 
to  fill  the  body's  resources  and  cause 
therapeutic  properties.  Walker  et  al. 
prescribed  2  months  of  200  mg  magnesium 
oxide  supplementation  for  38  women 
suffering from premenstrual syndrome. They 
found that 1 month of supplementation with 
magnesium  oxide  had  no  significant  effects 
on the symptoms of the syndrome. However, Ebrahimi et al. 
 
188 | Journal of Caring Sciences, December 2012; 1(4), 183-189  Copyright © 2012 by Tabriz University of Medical Sciences 
continuing supplementation until the second 
month significantly affected the symptoms.18 
On  the  other  hand,  the  difference  between 
the  findings  of  the  current  study  and  the 
study by Desouza et al. may be due to higher 
dosage  of  magnesium  in  the  current  study 
which  increased  the  bioavailability  of 
magnesium oxide.22 
Finally,  we  should  review  the  effect  of 
placebo  on  premenstrual  syndrome.  Many 
studies on this syndrome have found placebo 
to have significant effects on treatment of this 
syndrome.23 The response rate to placebo has 
been normally reported as 30-40%. It appears 
that  receiving  attention  could  positively 
affect  the  mental  status  of  the  participants 
and  thus  the  treatment  of  premenstrual 
syndrome.24  In  the  study  by  Desouza  et  al. 
placebo  caused  a  significant  decrease  in  all 
symptoms  of  premenstrual  syndrome.  This 
reduction  ranged  from  16%  in  symptoms 
relating  to  depression  to  31%  in  symptoms 
relating to water retention.22  
Overall,  compared  to  chemical  medications, 
magnesium is a beneficial, low cost, and effective 
treatment  for  the  symptoms  of  premenstrual 
syndrome. Therefore, considering the cyclical and 
chronic  nature  of  premenstrual  syndrome, 
prescription of magnesium seems reasonable. 
Conclusion 
Considering the importance of premenstrual 
syndrome and the numerous effects it has on 
society  and  the  lives  of  women,  health 
groups  should  prioritize  the  diagnosis  and 
treatment of this syndrome. Since there is no 
definitive  etiology  and  treatment  for  this 
syndrome,  many  researchers  have  tried  to 
find the best and most effective drug with the 
least side effects to prevent the occurrence of 
the  syndrome.  Each  researcher  has  thus 
proposed suggestions for the enhancement of 
future  studies.  The  current  study  was  also 
undertaken  with  the  goal  of  finding  an 
effective  compound  with  no  side  effects  to 
reduce the symptoms of this syndrome and 
its  direct  and  indirect  economic  and  social 
effects.  All  compounds  used  in  the  current 
study had no side effects, were effective, non-
chemical, and acceptable by most groups of 
women in the society. Hence, health groups, 
especially  midwives,  can  compare  the 
effectiveness the compound on their specific 
patients  and  select  the  most  appropriate 
treatment  for  each  individual.  Moreover,  in 
cases  where  the  patient  is  prohibited  from 
using  chemical  drugs  to  treat  premenstrual 
syndrome,  such  as  oral  contraceptive  pills 
and  gonadotropin  releasing  hormone 
(GnRH) agonists, the use of these compounds 
seems effective. However, the prescription of 
high dosages of every drug should be done 
with caution. 
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